IBTK and lymphoproliferative syndrome: The lower risk of seroconversion for patients treated with anti‐CD20 or BTKI was even clearer when analyzing the subgroup of patients affected by lymphoproliferative disorders, in whom a recent treatment with anti‐CD20 or BTKI reduced the likelihood of seroconversion by 74% and 65%, respectively (Table S6).